This SEER database study analyzed 2.2 million adult patients diagnosed with solid tumors from 2010–2016. It is the first study to systematically estimate bone metastasis incidence at initial diagnosis across all major cancer types using the full SEER dataset. The study reports cancer-specific incidence rates, survival after bone metastasis, and the prognostic impact of co-existing metastatic sites.
Every orthopedic surgeon treating pathologic fractures needs a mental model of which primaries destroy bone and how long those patients will live. Prior estimates were single-cancer studies that couldn't be compared across tumor types, and population-level data for cancers like esophageal and bladder were absent entirely.
When a patient with metastatic prostate, breast, or renal cancer presents with bone pain or a fracture, bone involvement is the expected finding. Plan for it at staging. For lung cancer, the absolute case volume means you will fix more pathologic fractures from lung primaries than from any other cancer, even though individual rates look lower.
Two groups warrant bone screening that current guidelines did not mandate at the time of this paper: stage IV NSCLC (ADC reaches 36.86% among metastatic patients) and metastatic esophageal cancer (20.74%). If you see a patient with either diagnosis and musculoskeletal complaints, do not wait for a skeletal-related event to identify bone disease.
When you identify bone metastasis, check for brain, liver, and lung involvement systematically. In lung ADC, bone plus liver co-occurrence exceeds 53%. Multi-site disease predicts sharply worse survival and should drive the palliative framing of any surgical intervention — the pancreatic cancer patient with a femur fracture has a 2-month median survival regardless of how good your fixation is.
This SEER database study analyzed 2.2 million adult patients diagnosed with solid tumors from 2010–2016. It is the first study to systematically estimate bone metastasis incidence at initial diagnosis across all major cancer types using the full SEER dataset. The study reports cancer-specific incidence rates, survival after bone metastasis, and the prognostic impact of co-existing metastatic sites.
Every orthopedic surgeon treating pathologic fractures needs a mental model of which primaries destroy bone and how long those patients will live. Prior estimates were single-cancer studies that couldn't be compared across tumor types, and population-level data for cancers like esophageal and bladder were absent entirely.
When a patient with metastatic prostate, breast, or renal cancer presents with bone pain or a fracture, bone involvement is the expected finding. Plan for it at staging. For lung cancer, the absolute case volume means you will fix more pathologic fractures from lung primaries than from any other cancer, even though individual rates look lower.
Two groups warrant bone screening that current guidelines did not mandate at the time of this paper: stage IV NSCLC (ADC reaches 36.86% among metastatic patients) and metastatic esophageal cancer (20.74%). If you see a patient with either diagnosis and musculoskeletal complaints, do not wait for a skeletal-related event to identify bone disease.
When you identify bone metastasis, check for brain, liver, and lung involvement systematically. In lung ADC, bone plus liver co-occurrence exceeds 53%. Multi-site disease predicts sharply worse survival and should drive the palliative framing of any surgical intervention — the pancreatic cancer patient with a femur fracture has a 2-month median survival regardless of how good your fixation is.